Article in Nature chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Zheng ZhangDepartment of Biochemistry, Purdue University, West Lafayette, IN, USA.ORCID 0000-0001-9190-8900
Yi-Kai LiuDepartment of Biochemistry, Purdue University, West Lafayette, IN, USA.
Zhuojun LuoDepartment of Biochemistry, Purdue University, West Lafayette, IN, USA.
Meng-Ju WuCancer Center, Massachusetts General Hospital, Department of Medicine, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-6847-7065
Claudia N EvansJames Tarpo Jr. and Margaret Tarpo Department of Chemistry, Purdue University, West Lafayette, IN, USA.
Zihan QuJames Tarpo Jr. and Margaret Tarpo Department of Chemistry, Purdue University, West Lafayette, IN, USA.
Fanglei XueUniversity of Technology Sydney, Sydney, New South Wales, Australia.ORCID 0000-0002-1848-2322
Zhijian WangSchool of Materials Engineering, Purdue University, West Lafayette, IN, USA.
Lia StanciuSchool of Materials Engineering, Purdue University, West Lafayette, IN, USA.
Zhong-Yin ZhangJames Tarpo Jr. and Margaret Tarpo Department of Chemistry, Purdue University, West Lafayette, IN, USA.ORCID 0000-0001-5527-7910
Elizabeth I ParkinsonJames Tarpo Jr. and Margaret Tarpo Department of Chemistry, Purdue University, West Lafayette, IN, USA.ORCID 0000-0002-3665-5522
Nabeel BardeesyCancer Center, Massachusetts General Hospital, Department of Medicine, Harvard Medical School, Boston, MA, USA.
W Andy TaoDepartment of Biochemistry, Purdue University, West Lafayette, IN, USA. watao@purdue.edu.ORCID 0000-0002-5535-5517
Funding
Transgenic Mouse Core Facility Shared Resource (TMCF-SR)P30CA023168 · NCI · PURDUE UNIVERSITY WEST LAFAYETTE · PI ANDREW D MESECAR · 1985 to 2026
$43.4M
Tissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI SHIVDASANI, RAMESH A · 2007 to 2023
$33.2M
Structure/Function of Protein Tyrosine PhosphatasesR01CA069202 · NCI · YESHIVA UNIVERSITY · PI Zhong-Yin Zhang · 1996 to 2026
$7.3M
Mining Cryptic Biosynthetic Gene Clusters for Novel Bioactive Compounds and BiocatalystsR35GM138002 · NIGMS · PURDUE UNIVERSITY · PI Elizabeth Ivy Parkinson · 2020 to 2026
$2.9M
Functions of mutant IDH in cholangiocarcinomaR01CA280085 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI NABEEL El-BARDEESY · 2023 to 2026
$2.6M
Harnessing mutant IDH1 as a therapeutic target in liver cancer and other solid malignanciesR01CA292508 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI NABEEL El-BARDEESY, Robert Thomas Manguso · 2025 to 2026
$1.4M
Dissecting signaling pathways and seeking EV phosphoproteins as novel biomarkers for Alzheimer's DiseaseR01AG064250 · NIA · PURDUE UNIVERSITY · PI TAO, W. ANDY · 2024 to 2024
$386k
NCI NIH HHS P30 CA023168NCI NIH HHS P50 CA127003NCI NIH HHS R01 CA069202NCI NIH HHS R01 CA280085NCI NIH HHS R01 CA292508NIA NIH HHS R01 AG064250NIGMS NIH HHS R35 GM138002NSF | Directorate for Mathematical & Physical Sciences | Division of Chemistry (CHE) 2404098-CHEU.S. Department of Health & Human Services | National Institutes of Health (NIH) 1R35GM138002U.S. Department of Health & Human Services | National Institutes of Health (NIH) 2R001CA069202U.S. Department of Health & Human Services | National Institutes of Health (NIH) 4R01AG064250
6 · The paper itself
Abstract
Mutations in isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) are common in multiple types of human cancer and cause accumulation of the oncometabolite D-2-hydroxyglutarate (D2HG) instead of α-ketoglutarate, driving cancers like gliomas and acute myeloid leukaemia by blocking cell differentiation and promoting tumour growth. Here we discovered protein O-2-hydroxyglutarylation by D2HG using chemical proteomics and further revealed distinct chiral preferences for D2HG and L-2-hydroxyglutarate (L2HG) modifications. D2HG modifications are upregulated in IDH-mutant cells or upon D2HG treatment, while L2HG modifications increase under hypoxic conditions or following L2HG treatment. Notably, two kinases MRCKA and SLK are modified by D2HG and L2HG, respectively, and confirmed by synthetic peptide standards. Phosphoproteomics revealed reduced phosphorylation of MRCKA and SLK substrates, suggesting crosstalk between D/L-2HG modification and kinase activity. These findings highlight distinctive roles of D/L-2HG modifications in cancer progression and suggest potential avenues for therapeutic targeting of oncometabolite-induced post-translational modifications.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Discovery of chirally dependent protein modifications by D- and L-2-hydroxyglutarates. · full record | OpenQuestion